---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-320009"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:08:58.707258+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nektar Phase2b REZOLVE-AA: primary endpoint missed; significant after excluding 4 violators. Plans Phase3.

## Summary
- Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).
- Excluding 4 patients with major eligibility violations: 29.6%, 30.4% vs 5.7% (p=0.049, p=0.042), meeting significance.
- Key secondary endpoints (SALT30, SALT≤30, SALT≤20, SALT≤10) showed dose-dependent improvement vs placebo.
- Safety well-tolerated; discontinuation rate due to AEs 1.4%, no discontinuations from injection site reactions.
- Plans to present results at a medical conference in 2026; 16-week extension data expected early Q2 2026; advancing to Phase 3.

## SEC filing metadata
- accession: 0001193125-25-320009
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000119312525320009/0001193125-25-320009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000119312525320009/d24251d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-320009
- JSON: https://secwatch.observer/filing/0001193125-25-320009.json
- Plain text: https://secwatch.observer/filing/0001193125-25-320009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.